Canagliflozin Improves Anemia in Diabetics with Renal ImpairmentByKenneth Bender, PharmD, MAJanuary 4th 2021The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.
FDA Expedites Review of Promacta for Severe Aplastic AnemiaByCecilia Pessoa GingerichMay 30th 2018Eltrombopag (Promacta) was granted Priority Review designation, indicating a 6-month timeline for review.